JP2009536617A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536617A5
JP2009536617A5 JP2009505430A JP2009505430A JP2009536617A5 JP 2009536617 A5 JP2009536617 A5 JP 2009536617A5 JP 2009505430 A JP2009505430 A JP 2009505430A JP 2009505430 A JP2009505430 A JP 2009505430A JP 2009536617 A5 JP2009536617 A5 JP 2009536617A5
Authority
JP
Japan
Prior art keywords
aliphatic
compound
disease
formula
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009505430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/008819 external-priority patent/WO2007117692A2/en
Publication of JP2009536617A publication Critical patent/JP2009536617A/ja
Publication of JP2009536617A5 publication Critical patent/JP2009536617A5/ja
Pending legal-status Critical Current

Links

JP2009505430A 2006-04-11 2007-04-11 タンパク質キナーゼの阻害剤として有用なチアゾール、イミダゾール、およびピラゾール Pending JP2009536617A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79108306P 2006-04-11 2006-04-11
PCT/US2007/008819 WO2007117692A2 (en) 2006-04-11 2007-04-11 Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases

Publications (2)

Publication Number Publication Date
JP2009536617A JP2009536617A (ja) 2009-10-15
JP2009536617A5 true JP2009536617A5 (enExample) 2011-05-12

Family

ID=38508761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505430A Pending JP2009536617A (ja) 2006-04-11 2007-04-11 タンパク質キナーゼの阻害剤として有用なチアゾール、イミダゾール、およびピラゾール

Country Status (9)

Country Link
US (3) US7589214B2 (enExample)
EP (1) EP2007732B1 (enExample)
JP (1) JP2009536617A (enExample)
CN (1) CN101460466B (enExample)
AT (1) ATE534632T1 (enExample)
AU (1) AU2007235237B2 (enExample)
CA (1) CA2648923A1 (enExample)
ES (1) ES2376765T3 (enExample)
WO (1) WO2007117692A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460466B (zh) * 2006-04-11 2012-06-13 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的噻唑类、咪唑类和吡唑类
CN102414199B (zh) * 2009-04-24 2014-03-05 泰博特克药品公司 二芳基醚
MA33926B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
WO2011075560A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのピリジルアミノピリジン
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
EP2706853B1 (en) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
WO2013098313A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Hetero-bicyclic derivatives as hcv inhibitors
EP2882741B1 (en) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2014068527A1 (en) * 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8895750B2 (en) 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
US8940893B2 (en) 2013-03-15 2015-01-27 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
WO2015048662A2 (en) 2013-09-30 2015-04-02 X-Rx Discovery, Inc. Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
JP6263626B2 (ja) 2013-12-13 2018-01-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼのインヒビター
US9828364B2 (en) 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
TW201607930A (zh) * 2014-07-18 2016-03-01 百濟神州有限公司 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
KR102691112B1 (ko) 2015-12-16 2024-08-05 베링거 인겔하임 인터내셔날 게엠베하 자가 면역 질환의 치료에 유용한 비피라졸릴 유도체
EP3402789B1 (en) 2016-01-13 2020-03-18 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
EP3931182A4 (en) * 2019-02-25 2023-01-25 Beijing InnoCare Pharma Tech Co., Ltd. PROCESS FOR THE PREPARATION OF 6-(1-ACRYLOYLPIPERIDINE-4-YL)-2-(4-PHENOXYPHENYL)NICOTINAMIDE
WO2022012550A1 (en) * 2020-07-13 2022-01-20 Henan Normal University Substituted 1h-imidazo [1, 2-b] pyrazole-3-carboxamide as bruton's tyrosine kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US6288061B1 (en) * 1997-12-26 2001-09-11 Welfide Corporation Imidazole derivatives
AU2001296871A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002064136A2 (en) * 2001-01-26 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
CA2532965C (en) * 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
WO2005123671A1 (ja) * 2004-06-22 2005-12-29 Taisho Pharmaceutical Co., Ltd. ピロール誘導体
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
CN101460466B (zh) * 2006-04-11 2012-06-13 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的噻唑类、咪唑类和吡唑类

Similar Documents

Publication Publication Date Title
JP2009536617A5 (enExample)
EP3515916B1 (en) Shp2 phosphatase inhibitors and methods of use thereof
ES2543216T3 (es) Moduladores de tiazolopirimidina como agentes inmunosupresores
ES2935633T3 (es) Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
KR102760314B1 (ko) 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구 투여용 약학 조성물
CN113423685A (zh) 整合应激通路的前药调节剂
AU2018203833A1 (en) Tetracyclic bromodomain inhibitors
JP2020528889A5 (enExample)
JP2021501779A (ja) 統合的ストレス経路の調節剤
JP2022526854A (ja) ホスファチジルイノシトール３－キナーゼ阻害剤
JP2016538257A5 (enExample)
CN108553467A (zh) 改善膈肌功能的方法
TW201106951A (en) 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane-or heptane-nitrile as JAK inhibitors
CN101945655A (zh) 作为p2x7调节剂的5-氧代-3-吡咯烷甲酰胺衍生物
TW201917126A (zh) 二氫二酮
JP7672372B2 (ja) ４－アミノ－ｎ－（１－（（３－クロロ－２－フルオロフェニル）アミノ）－６－メチルイソキノリン－５－イル）チエノ［３，２－ｄ］ピリミジン－７－カルボキサミドの塩とその結晶形態
BR112015012842B1 (pt) Compostos derivados de diazol lactama, composição farmacêutica e uso dos mesmos
KR20170031786A (ko) 다발성 골수종을 치료하기 위한 약물 병용물
JP7025555B2 (ja) 一過性受容体電位ａ１イオンチャネルの阻害
CN109476600A (zh) 吡啶硫酮、其药物组合物及其用于治疗增殖性、炎症性、神经变性或免疫-介导的疾病的治疗用途
CA3176994A1 (en) Treatments of inflammatory bowel disease
CN105813643A (zh) 利用含有噻吩并三唑二氮杂*化合物的药物制剂治疗非小细胞肺癌的方法
US20070049608A1 (en) Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use
JP2020532581A5 (enExample)
DE60304596T2 (de) In 3-position heterocyclisch substituierte pyridoindolonderivate, ihre herstellung und ihre therapeutische verwendung